This double-blind, placebo-controlled, full cross-over trial (n=30) will study the effects of psilocybin (10mg/70kg) on brain activity and thought dynamics in healthy volunteers.
This double-blind, placebo-controlled, within-subject crossover study in healthy volunteers uses EEG and MRI during cognitive tasks and naturalistic stimuli to examine acute effects of psilocybin (10 mg/70 kg) on thought dynamics, creativity, memory, and shared versus individual brain responses.
Psilocybin and matching placebo are administered as size 0 blue gelatin capsules; sessions last approximately 6 hours with a washout between visits. Primary outcomes include electrophysiological measures, MRI responses, and behavioural task performance.
Single oral dose of psilocybin (10 mg/70 kg) in a full crossover design.
10 mg per 70 kg; encapsulated cGMP, size 0 blue gelatin capsule; acute effects ~6 hours.
Matching inert placebo capsule in crossover.
Microcrystalline cellulose in size 0 blue gelatin capsule.